Similar articles

• The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.

  Jennings HJ. Jennings HJ. Contrib Microbiol Immunol. 1989;10:151-65. Contrib Microbiol Immunol. 1989. PMID: 2479499 Review. No abstract available.
• Structure of a protective epitope reveals the importance of acetylation of Neisseria meningitidis serogroup A capsular polysaccharide.

  Henriques P, Dello Iacono L, Gimeno A, Biolchi A, Romano MR, Arda A, Bernardes GJL, Jimenez-Barbero J, Berti F, Rappuoli R, Adamo R. Henriques P, et al. Proc Natl Acad Sci U S A. 2020 Nov 24;117(47):29795-29802. doi: 10.1073/pnas.2011385117. Epub 2020 Nov 6. Proc Natl Acad Sci U S A. 2020. PMID: 33158970 Free PMC article.
• Status of a group B Neisseria meningitidis vaccine.

  Frasch CE. Frasch CE. Eur J Clin Microbiol. 1985 Dec;4(6):533-6. doi: 10.1007/BF02013388. Eur J Clin Microbiol. 1985. PMID: 3937731 Clinical Trial. No abstract available.
• Recurrent meningococcal meningitis due to partial complement defects and poor anti-meningococcal antibody response.

  Herva E, Leinonen M, Käyhty H, Mäkelä PH, Vetoniemi-Korhonen SL. Herva E, et al. J Infect. 1983 Jan;6(1):55-60. doi: 10.1016/s0163-4453(83)95636-0. J Infect. 1983. PMID: 6411822
• Interaction of complement with Neisseria meningitidis and Neisseria gonorrhoeae.

  Densen P. Densen P. Clin Microbiol Rev. 1989 Apr;2 Suppl(Suppl):S11-7. doi: 10.1128/CMR.2.Suppl.S11. Clin Microbiol Rev. 1989. PMID: 2497954 Free PMC article. Review. No abstract available.